Enjoy complimentary customisation on priority with our Enterprise License!
Research analysis on the global schizophrenia therapeutics market identifies that the emergence of enhanced next-generation products will have a positive impact on the market’s growth. Chlorpromazine, haloperidol, and fluphenazine are some of the first antipsychotic drugs, which are also known as first-generation or typical antipsychotic drugs. These drugs are not selective in nature and act at the D2 receptor site on the mesolimbic pathway. They are also used to block the D2 receptors present in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. However, with the introduction of second-generation antipsychotic drugs, first-generation drugs were largely out of practice. Clozapine, risperidone, olanzapine, quetiapine, and ziprasidone are some of the second-generation drugs, which are also known as atypical antipsychotic drugs. Researchers are increasingly focusing on the development of newer antipsychotic drugs with lesser side effects and enhanced efficacy. This encourages them to continuously manufacture enhanced antipsychotic drugs. According to the schizophrenia therapeutics industry analysis, this market will grow at a CAGR of close to 2% by 2021.
The increasing use of long-acting injectable (LAI) antipsychotic drugs is one of the key trends that will propel the growth prospects for the global schizophrenia therapeutics market for the next four years. The LAI antipsychotics drugs can attain higher efficacy in negative and cognitive predominant patients. They improve patient compliance because they are associated with both reduced hospitalization rates and reduced care costs.
The schizophrenia drugs market is fragmented due to the presence of many leading players. These vendors are increasingly competing against each other based on factors such as emerging indications or applications, major patent expiries, and the rising prevalence of mental disorder in the developed and developing countries. Vendors are losing their market revenue because the market is witnessing the patent expiry of major drugs over the last few years such as ZYPREXA by Eli Lilly and Seroquel by AstraZeneca.
Key vendors in this market are
Other prominent vendors in the market include Alkermes and Bristol-Myers Squibb.
The second-generation antipsychotic drugs segment accounted for the majority of market shares during 2016 because these drugs involve fewer side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improve the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This, in turn, will boost the segment’s growth throughout the estimated period.
Based on the schizophrenia therapeutics market overview, the Americas is experiencing sluggish growth due to patent expiry of major drugs such as Geodon, ZYPREXA, ABILIFY, SEROQUEL, and Prozac. However, vendors in the market are increasingly focusing on the development of DMD for schizophrenia. For instance, the American drug-maker AbbVie is taking efforts to develop schizophrenia treatment drug to treat the cognitive impairment associated with schizophrenia. Similarly, Amgen developed the schizophrenia drug AMG 581 for the treatment of schizophrenia and is conducting Phase I trials for the drug.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Schizophrenia: Disease overview
PART 06: Key clinical trials
PART 07: Market landscape
PART 08: Market segmentation based on drug-class
PART 09: Geographical segmentation
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.